LONDON — The longest study yet on prostate cancer testing provides more evidence that getting screened doesn't cut the chances of dying from the disease. In a 20-year study of more than 9,000 Swedish men, researchers found no difference in the rate of prostate cancer deaths between the men who were periodically screened and those who weren't.

Routine screening for prostate cancer is controversial and the new results aren't likely to end the debate about the value of testing. Critics say screening leads to unnecessary biopsies and treatment with little proof that it saves lives.

Testing is done with a physical exam and a PSA blood test. "There is no escaping the fact that we need a better tool … to help detect prostate cancers that actually need treating, as opposed to innocent ones that do not," said Malcolm Mason, a prostate cancer expert at Cancer Research U.K. in a statement.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.